Let me tell you, folks, we’ve got something incredible here. We’re talking about Parkinson’s disease, a big deal, a huge problem for many people. And there’s this idea, believe me, it’s been around, that dopamine and mitochondria, they’re in this fight, a big fight inside the body. But what happens when we throw more dopamine into the mix? Nobody knew, until now.

We did something fantastic, a study, a big one, and it was double-blinded, cross-over, placebo-controlled. The best kind. We gave people, real people with Parkinson’s and also healthy people, this drug, levodopa/benserazide, or a placebo. And then, we switched it up. We looked inside their brains, with this super advanced technique, ³¹ phosphorus magnetic resonance spectroscopy. We looked at the basal ganglia and the midbrain, very important parts of the brain.

Here’s the deal: 20 patients with Parkinson’s, and 22 healthy people, perfectly matched, participated. And when we gave them the drug, not the placebo, something amazing happened. In the basal ganglia, the energy, those high-energy phosphorus things, they went down by 40% in both groups. But in the midbrain? Nothing changed. It tells you, the action is in the basal ganglia, not the midbrain.

So, what we’ve found here, and it’s huge, is that this drug, levodopa/benserazide, it really does something. It’s not just any effect, it’s a big effect, but only where it matters, in the basal ganglia. This is big news, folks, for everyone dealing with Parkinson’s. ANN NEUROL 2024, remember that. We’re making progress, big progress, and it’s going to be fantastic.